Mazdutide* · IBI362*
Researchers seeking this product for laboratory research can explore PepGen-X.com as a supplier specializing in research-use compounds.
Mazdutide (IBI362) is a dual GLP-1 and glucagon receptor agonist being investigated for weight management and metabolic health. By combining GLP-1 activity with glucagon signaling, Mazdutide is designed to address both appetite regulation and energy metabolism. Clinical research has reported meaningful reductions in body weight along with improvements in several metabolic markers.
Research Benefits
• Dual-action metabolic signaling — combines GLP-1 appetite regulation with glucagon receptor activity
• Significant weight-loss potential — clinical studies have reported approximately 10–14% body-weight reduction at 24 weeks, depending on dose and study population
• Strong metabolic research potential — investigated for effects on glucose, lipids, body weight, and other metabolic markers
• Liver-fat research — clinical studies have investigated potential improvements in liver fat and metabolic-associated fatty liver disease
• May increase energy expenditure — glucagon receptor activation is being studied for its potential contribution to energy metabolism
• Once-weekly research formulation — developed as a long-acting injectable compound
Identified Risks & Side Effects
• Nausea, diarrhea, and vomiting are among the commonly reported gastrointestinal effects
• Glucagon activity can influence blood glucose and requires careful study
• Long-term safety remains under investigation
• Clinical evidence has primarily come from studies conducted in China
• Regulatory status varies by country and the compound remains investigational in many markets
• Not FDA-approved
Route: Subcutaneous
Frequency: Once weekly in clinical research
FDA Status: Investigational
Researcher Note
Mazdutide is particularly interesting because it combines two complementary metabolic pathways in a single molecule. GLP-1 activity contributes to appetite and glucose regulation, while glucagon signaling is being investigated for its potential effects on energy expenditure and liver metabolism. This dual mechanism has made Mazdutide an important subject in the next generation of metabolic research.
Disclaimer
FDA Status: Not FDA-approved
Research Classification: Research use only
Compound Type: Dual GLP-1 / glucagon receptor agonist
All products are intended strictly for research and laboratory use only and are not intended for human or veterinary use.